The finding of Ghallab et al. indicated that CXCR2 and TGF-β signaling were highly expressed in human triple-negative breast cancer biopsies, and CXCR2 inhibitor AZD5069 abrogated doxorubicin-induced TGF-β upregulation and eliminated chemoresistance in triple-negative breast cancer cells [40]. The gene discussed is TGFB1; the disease is triple-negative breast carcinoma.